The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine

Hyun Woong Lee, Sung Hee Lee, Min Goo Lee, SangHoon Ahn, Hye Young Chang, KwangHyub Han

Research output: Contribution to journalArticle

Abstract

Deoxycytidine kinase (dCK) is a critical enzyme involved in intracellular phosphorylation of lamivudine (LAM) to its active triphosphates. We conducted this study to determine dCK polymorphisms in Koreans and to evaluate whether the discovered single nucleotide polymorphisms (SNPs) were associated with treatment outcomes in chronic hepatitis B (CHB) patients treated with LAM. The full-length dCK gene was sequenced from 24 healthy volunteers and 24 patients with CHB. One hundred twenty-seven patients with CHB who were followed-up for at least 24 months after LAM treatment were enrolled. Virological response as determined by undetectable HBV DNA was defined as a good drug response. Primary non-response at 6 months and virological breakthrough within 12 months were defined as a poor drug response. Six novel dCK SNPs were found (-2052C/A, IVS3-46G/del, IVS4+40G/T, IVS5+39T/C, IVS5-72A/T, and 966-975T 10 /T 11 ). In particular, two promoter SNPs, namely -360C/G and -201C/T, were in full linkage disequilibrium. These two SNPs had a higher allele frequency than previously reported in Caucasian, Japanese, and Chinese (26% vs. 2%, 13.1%, and 15.6%, respectively). There was no significant difference between treatment response groups in terms of the distributions of SNP genotypes or allele frequencies. However, there was significant difference in the allele frequency of -360G/-201T between HBeAg seroclearance group and HBeAg non-seroclearance group (P=0.045). In conclusion, six novel dCK SNPs were discovered. Two promoter SNPs, namely -360C/G and -201C/T, were more frequent in Koreans than other populations. In particular, HBeAg-positive patients with the -360G/-201T haplotype may help HBeAg seroclearance in response to LAM therapy.

Original languageEnglish
Pages (from-to)820-827
Number of pages8
JournalJournal of Medical Virology
Volume88
Issue number5
DOIs
Publication statusPublished - 2016 May 1

Fingerprint

Deoxycytidine Kinase
Lamivudine
Chronic Hepatitis B
Single Nucleotide Polymorphism
Hepatitis B e Antigens
Gene Frequency
Linkage Disequilibrium
Pharmaceutical Preparations
Haplotypes
Healthy Volunteers
Therapeutics
Genotype
Phosphorylation
DNA
Enzymes

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

Cite this

@article{d44d810247a74e59a99f8470e58b8db7,
title = "The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine",
abstract = "Deoxycytidine kinase (dCK) is a critical enzyme involved in intracellular phosphorylation of lamivudine (LAM) to its active triphosphates. We conducted this study to determine dCK polymorphisms in Koreans and to evaluate whether the discovered single nucleotide polymorphisms (SNPs) were associated with treatment outcomes in chronic hepatitis B (CHB) patients treated with LAM. The full-length dCK gene was sequenced from 24 healthy volunteers and 24 patients with CHB. One hundred twenty-seven patients with CHB who were followed-up for at least 24 months after LAM treatment were enrolled. Virological response as determined by undetectable HBV DNA was defined as a good drug response. Primary non-response at 6 months and virological breakthrough within 12 months were defined as a poor drug response. Six novel dCK SNPs were found (-2052C/A, IVS3-46G/del, IVS4+40G/T, IVS5+39T/C, IVS5-72A/T, and 966-975T 10 /T 11 ). In particular, two promoter SNPs, namely -360C/G and -201C/T, were in full linkage disequilibrium. These two SNPs had a higher allele frequency than previously reported in Caucasian, Japanese, and Chinese (26{\%} vs. 2{\%}, 13.1{\%}, and 15.6{\%}, respectively). There was no significant difference between treatment response groups in terms of the distributions of SNP genotypes or allele frequencies. However, there was significant difference in the allele frequency of -360G/-201T between HBeAg seroclearance group and HBeAg non-seroclearance group (P=0.045). In conclusion, six novel dCK SNPs were discovered. Two promoter SNPs, namely -360C/G and -201C/T, were more frequent in Koreans than other populations. In particular, HBeAg-positive patients with the -360G/-201T haplotype may help HBeAg seroclearance in response to LAM therapy.",
author = "Lee, {Hyun Woong} and Lee, {Sung Hee} and Lee, {Min Goo} and SangHoon Ahn and Chang, {Hye Young} and KwangHyub Han",
year = "2016",
month = "5",
day = "1",
doi = "10.1002/jmv.24393",
language = "English",
volume = "88",
pages = "820--827",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "5",

}

The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine. / Lee, Hyun Woong; Lee, Sung Hee; Lee, Min Goo; Ahn, SangHoon; Chang, Hye Young; Han, KwangHyub.

In: Journal of Medical Virology, Vol. 88, No. 5, 01.05.2016, p. 820-827.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine

AU - Lee, Hyun Woong

AU - Lee, Sung Hee

AU - Lee, Min Goo

AU - Ahn, SangHoon

AU - Chang, Hye Young

AU - Han, KwangHyub

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Deoxycytidine kinase (dCK) is a critical enzyme involved in intracellular phosphorylation of lamivudine (LAM) to its active triphosphates. We conducted this study to determine dCK polymorphisms in Koreans and to evaluate whether the discovered single nucleotide polymorphisms (SNPs) were associated with treatment outcomes in chronic hepatitis B (CHB) patients treated with LAM. The full-length dCK gene was sequenced from 24 healthy volunteers and 24 patients with CHB. One hundred twenty-seven patients with CHB who were followed-up for at least 24 months after LAM treatment were enrolled. Virological response as determined by undetectable HBV DNA was defined as a good drug response. Primary non-response at 6 months and virological breakthrough within 12 months were defined as a poor drug response. Six novel dCK SNPs were found (-2052C/A, IVS3-46G/del, IVS4+40G/T, IVS5+39T/C, IVS5-72A/T, and 966-975T 10 /T 11 ). In particular, two promoter SNPs, namely -360C/G and -201C/T, were in full linkage disequilibrium. These two SNPs had a higher allele frequency than previously reported in Caucasian, Japanese, and Chinese (26% vs. 2%, 13.1%, and 15.6%, respectively). There was no significant difference between treatment response groups in terms of the distributions of SNP genotypes or allele frequencies. However, there was significant difference in the allele frequency of -360G/-201T between HBeAg seroclearance group and HBeAg non-seroclearance group (P=0.045). In conclusion, six novel dCK SNPs were discovered. Two promoter SNPs, namely -360C/G and -201C/T, were more frequent in Koreans than other populations. In particular, HBeAg-positive patients with the -360G/-201T haplotype may help HBeAg seroclearance in response to LAM therapy.

AB - Deoxycytidine kinase (dCK) is a critical enzyme involved in intracellular phosphorylation of lamivudine (LAM) to its active triphosphates. We conducted this study to determine dCK polymorphisms in Koreans and to evaluate whether the discovered single nucleotide polymorphisms (SNPs) were associated with treatment outcomes in chronic hepatitis B (CHB) patients treated with LAM. The full-length dCK gene was sequenced from 24 healthy volunteers and 24 patients with CHB. One hundred twenty-seven patients with CHB who were followed-up for at least 24 months after LAM treatment were enrolled. Virological response as determined by undetectable HBV DNA was defined as a good drug response. Primary non-response at 6 months and virological breakthrough within 12 months were defined as a poor drug response. Six novel dCK SNPs were found (-2052C/A, IVS3-46G/del, IVS4+40G/T, IVS5+39T/C, IVS5-72A/T, and 966-975T 10 /T 11 ). In particular, two promoter SNPs, namely -360C/G and -201C/T, were in full linkage disequilibrium. These two SNPs had a higher allele frequency than previously reported in Caucasian, Japanese, and Chinese (26% vs. 2%, 13.1%, and 15.6%, respectively). There was no significant difference between treatment response groups in terms of the distributions of SNP genotypes or allele frequencies. However, there was significant difference in the allele frequency of -360G/-201T between HBeAg seroclearance group and HBeAg non-seroclearance group (P=0.045). In conclusion, six novel dCK SNPs were discovered. Two promoter SNPs, namely -360C/G and -201C/T, were more frequent in Koreans than other populations. In particular, HBeAg-positive patients with the -360G/-201T haplotype may help HBeAg seroclearance in response to LAM therapy.

UR - http://www.scopus.com/inward/record.url?scp=84959362039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959362039&partnerID=8YFLogxK

U2 - 10.1002/jmv.24393

DO - 10.1002/jmv.24393

M3 - Article

C2 - 26400223

AN - SCOPUS:84959362039

VL - 88

SP - 820

EP - 827

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 5

ER -